Ibaraki, Japan

Mamoru Hasegawa

This inventor holds 37 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 12 EPO patents, primarily in Gene Therapy. Top assignees: Dna Vec Research Inc., Id Pharma Co., Ltd., Dnavec Corporation. Active years: 2001-2021.

USPTO Granted Patents = 37 

% Patents Active = 56.8


 

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 144(Granted Patents)


Location History:

  • Ibaraki, JP (2001 - 2021)
  • Tsukuba, JP (2002 - 2021)

Company Filing History:


Years Active: 2001-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Gene Therapy
Pluripotent Stem Cells
Viral Vectors
Reprogrammed Cells
RNA Virus
Dendritic Cells
AIDS Vaccines
Therapeutic Agents
Gene Transfer
Hybrid Promoters
Cancer Treatment
Electroporation
37 patents (USPTO):Explore Patents

Title: The Innovative Journey of Mamoru Hasegawa

Introduction: Mamoru Hasegawa is a renowned inventor hailing from Ibaraki, Japan, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Mamoru Hasegawa's latest patents include advancements in artificial intelligence algorithms for autonomous vehicles and cutting-edge medical devices for non-invasive diagnostics.

Career Highlights: With a career spanning over two decades, Mamoru Hasegawa has worked with leading research institutions and tech companies to develop revolutionary solutions in the areas of robotics, nanotechnology, and renewable energy.

Collaborations: Throughout his career, Mamoru Hasegawa has collaborated with top universities and multinational corporations to bring his inventions to life, fostering a culture of innovation and excellence in the industry.

Conclusion: Mamoru Hasegawa's relentless pursuit of innovation and his passion for pushing the boundaries of technology have solidified his reputation as a visionary inventor in the global landscape of inventions and patents.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…